More about

Retinal Disease

News
October 04, 2019
1 min read
Save

Open access testing, counseling available for inherited retinal disease patients

A new open access program from Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness will allow patients with inherited retinal disease to receive no-cost genetic testing and genetic counseling in the United States, according to a press release.

News
September 25, 2019
1 min read
Save

FDA fast tracks potential treatment to prevent proliferative vitreoretinopathy

The FDA has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy, Aldeyra Therapeutics announced in a press release.

News
September 18, 2019
1 min read
Save

Ocugen gene therapy receives orphan drug designation

OCU400, a gene therapy candidate, has received a second orphan drug designation from the FDA for the treatment of CEP290 mutation associated retinal disease, Ocugen announced in a press release.

News
September 17, 2019
1 min read
Save

Xephilio OCT-A1 receives 510(k) clearance

The FDA has granted 510(k) clearance to Canon U.S.A.’s Xephilio OCT-A1 OCT device, according to a press release.

News
August 23, 2019
1 min read
Save

ONL raises $3 million in financing to advance Fas inhibitor study

ONL Therapeutics will begin a first-in-human study of its Fas inhibitor for retinal diseases following the completion of $3 million in convertible note financing, according to a press release.

News
August 23, 2019
1 min read
Save

Iconic, Novartis sign ophthalmology option agreement

Iconic Therapeutics has signed an agreement with Novartis that will give Novartis an option on Iconic’s ophthalmology program, according to a press release.

News
August 13, 2019
1 min read
Save

FDA approves Eylea prefilled syringe

The FDA has approved a chemistry, manufacturing and controls prior-approval supplement for the Eylea injection prefilled syringe, Regeneron announced in a press release.

View more